B and BIOAB Related Headlines
Go Back- Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
- BioArctic and Eisai sign research evaluation agreement regarding BAN2802
- The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
- Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
- BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
- Leqembi® approved for the treatment of Alzheimer's disease in China
- LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20
- Lecanemab winner in two categories at The Scrip Awards 2023
- LEQEMBI® Q3 2023 sales published - 0.4 billion yen recorded in the period
- Lecanemab named one of the world's best inventions in 2023 by TIME
- New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD
- 'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan
- BioArctic receives patent in Japan for new antibodies targeting Parkinson's disease
- Latest analysis of lecanemab's effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference
- Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC) 2023
- FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's disease
- FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer's disease
- Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease filed in South Korea
- Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic
- Societal value of lecanemab in Japan published in Neurology and Therapy
- Health Canada accepts New Drug Submission for lecanemab as treatment for early Alzheimer's disease
B and BIOAB Related Press Releases
Go Back- Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
- BioArctic and Eisai sign research evaluation agreement regarding BAN2802
- The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
- Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
- BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
- Leqembi® approved for the treatment of Alzheimer's disease in China
- LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20
- Lecanemab winner in two categories at The Scrip Awards 2023
- LEQEMBI® Q3 2023 sales published - 0.4 billion yen recorded in the period
- Lecanemab named one of the world's best inventions in 2023 by TIME
- New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD
- 'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan
- BioArctic receives patent in Japan for new antibodies targeting Parkinson's disease
- Latest analysis of lecanemab's effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference
- Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC) 2023
- FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's disease
- FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer's disease
- Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease filed in South Korea
- Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic
- Societal value of lecanemab in Japan published in Neurology and Therapy
- Health Canada accepts New Drug Submission for lecanemab as treatment for early Alzheimer's disease
